先天免疫反应在慢性髓性白血病复发或急变中的作用
该研究在慢性髓性白血病(CML)细胞中发现钙蛋白酶(calpain)相对抑制导致βcatenin和Xiap1稳定,分别激活Survivin和Xiap1以抵抗凋亡。在小鼠CML模型中,抑制Survivin(而非Xiap1)可预防TKI治疗期间及停药后的复发。转录组分析显示先天免疫反应通路在CML骨髓祖细胞中激活,TKI治疗增强该激活,加用Survivin抑制剂后恢复正常。先天免疫反应激活可诱导未治疗CML小鼠快速急变,并在TKI停药尝试中导致慢性期复发。
要点
- CML细胞中calpain抑制稳定βcatenin和Xiap1,分别通过Survivin和Xiap1抵抗凋亡。
- 小鼠模型中抑制Survivin可预防TKI治疗期间及停药后复发,抑制Xiap1无效。
- 先天免疫反应通路激活与CML急变和停药后复发相关,Survivin抑制剂可使其正常化。
核心结论
- CML细胞中calpain相对抑制稳定βcatenin和Xiap1,分别激活Survivin和Xiap1以抵抗凋亡。
- 抑制Survivin可预防小鼠CML在TKI治疗期间及停药后的复发。
- 先天免疫反应通路激活可诱导CML急变和停药后复发,Survivin抑制剂可逆转其激活。
研究设计与样本
- 研究采用CML细胞系和小鼠CML模型,结合转录组分析。
- 原文未明确报告样本量。
主要发现
- CML细胞中calpain相对抑制,calpain底物βcatenin和Xiap1稳定。
- Survivin抑制白血病干细胞(LSC)凋亡,Xiap1抑制CML粒细胞凋亡。
- 小鼠CML模型中,Survivin抑制剂(而非Xiap1抑制剂)预防TKI治疗期间及停药后复发。
- 转录组分析显示小鼠CML骨髓祖细胞中先天免疫反应通路激活,TKI治疗增强,加用Survivin抑制剂后正常化。
- 先天免疫反应激活诱导未治疗CML小鼠快速急变,并在TKI停药尝试中导致慢性期复发。
关键数值与推荐
- 原文未报告具体数值、比例、阈值、剂量、样本量或P值。
临床怎么用
- 对于达到深度分子学反应并尝试停用TKI的CML患者,Survivin抑制可能作为预防复发的潜在策略。
- 先天免疫反应通路激活可能作为预测CML急变或停药后复发的生物标志物。
局限性
- 研究主要基于小鼠CML模型,人体数据未报告。
- Survivin抑制剂在CML患者中的安全性和有效性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic myeloid leukemia (CML) is characterized by expression of the tyrosine kinase oncogene, Bcr-abl. Tyrosine kinase inhibitors (TKI) induce prolonged remission in CML, and therapy discontinuation is an accepted approach to patients with reduction in Bcr-abl transcripts of four logs or greater. Half such individuals sustain a therapy free remission, but molecular mechanisms predicting relapse are undefined. We found relative calpain inhibition in CML cells with stabilization of calpain substrates, including βcatenin and Xiap1. Since the Survivin gene is activated by βcatenin, this identified two apoptosis-resistance mechanisms. We found that Survivin impaired apoptosis in leukemia stem cells (LSCs) and Xiap1 in CML granulocytes. Consistent with this, we determined treatment with an inhibitor of Survivin, but not Xiap1, prevented relapse during TKI treatment and after therapy discontinuation in a murine CML model. By transcriptome profiling, we identified activation of innate immune response pathways in murine CML bone marrow progenitors. This was increased by TKI treatment alone, but normalized with addition of a Survivin inhibitor. We found that activation of the innate immune response induced rapid blast crisis in untreated CML mice, and chronic phase relapse during a TKI discontinuation attempt. These results suggest that extrinsic stress exerts adverse effects on CML-LSCs.
引用
- Huang W, Liu B, Eklund EA, et al. Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia. Leukemia. 2020. PMID: 32080344. doi:10.1038/s41375-020-0771-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。